&w=3840&q=100)
Venus Remedies gets GMP renewal certification from Ukraine's SMDC
The certification applies to the company's Unit-II manufacturing facility located in Baddi, Himachal Pradesh, covering its cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral production lines, including liquid and lyophilized injections, Venus Remedies said in a statement.
"Renewal of the Ukrainian GMP certification underlines our unwavering commitment to maintaining world-class manufacturing standards. This milestone not only reinforces our foothold in the Ukrainian market but also facilitates deeper penetration into PIC/S markets, significantly enhancing our international growth prospects," Venus Remedies President, Global Critical Care, Saransh Chaudhary said.
Ukraine, being a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consortium, comprising 56 countries spanning Europe, Asia, Oceania, and the Americas, further amplifies the global acceptance and strategic importance of this certification.
Venus Remedies already has a robust presence in 32 PIC/S countries, including South Africa, Thailand, Malaysia, Saudi Arabia, and Australia, with plans for continued expansion, it said.
The Ukrainian pharmaceutical market, projected to grow at a CAGR (compound annual growth rate) of 3.9 per cent and reach USD 822.26 million by 2029, is driven largely by increased demand for generics and oncology treatments.
Venus Remedies, with over two decades of experience in Ukraine and 44 product registrations to date, views this certification as pivotal for sustained growth and expanded access within the broader Asia Commonwealth of Independent States (CIS) region.
Aditi K Chaudhary, President, International Business, Venus Remedies Ltd, said, "Ukraine continues to be a key strategic market for us. This renewed GMP certification enhances our credibility with regulators and partners across the region, enabling us to deepen our market presence, expand product portfolios, and provide high-quality medicines to a wider patient base".
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
ICT Mumbai biocluster receives catalytic funding to boost translational biopharma research
Mumbai: In a significant boost to India's translational research ecosystem, ICT Mumbai's Biocluster secured Rs 30 crore in catalytic funding from the Indian Translational Research Institute (ITRI). The translational biopharmaceutical facility aims to bridge the gap between lab-stage research and clinical application. The eight-storey cluster will focus on rare diseases, synthetic biology, and AI-driven drug development. It will house a GMP-ready biologics pilot plant, shared R&D infrastructure, and advanced training zones for workforce development. Dr Ratnesh Jain, Principal Investigator of the project, said the Biocluster aims to make Indian biopharma globally competitive. ITRI CEO Dr Abdur Rub emphasised the need to de-risk innovation and scale healthcare solutions. Positioned as a national translational platform, the Mumbai Biocluster seeks to empower startups, academia, and industry alike—enabling faster, capital-efficient transitions from research to real-world impact. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai
India.com
2 hours ago
- India.com
No Rafale or F-35! Army Demands Rs 1.12 Lakh Cr Defence System, Gets Only Rs 36,000 Cr
New Delhi: After Operation Sindoor, India's defense upgrades are speeding ahead like a bullet train. With over Rs 3 lakh crore being pumped into military modernisation, the government is on a mission to acquire or indigenously develop fighter jets, submarines and advanced missile systems. One by one, big-ticket purchases are being cleared, and the pace is relentless. Earlier this month, the Ministry of Defence approved military procurements worth over Rs 1 lakh crore in one go. Among them, Rs 44,000 crore has been set aside for 12 Mine Counter Measure Vessels and Rs 36,000 crore has been sanctioned for six regiments of the Quick Reaction Surface-to-Air Missile system, better known as QRSAM. These six QRSAM regiments will be split evenly between the Indian Air Force and the Army. But here is the twist. This is only a fraction of what the armed forces actually asked for. The Army had demanded 11 regiments. What they got was only three. The Air Force's separate demand? Also unmet. If both services were to receive the full complement, 11 regiments each, the total cost would have soared to Rs 1.12 lakh crore. But the government stopped short. Enter the 'Baby S-400' Apart from being a missile defense system, QRSAM is being nicknamed the 'Baby S-400'. India already has three operational regiments of Russia's S-400 system and expects two more by next year. But defense planners know that S-400s and indigenous Akash systems alone cannot transform the country into a secure fortress. The threat matrix has changed. China is watching, and so is Pakistan. And they are not standing still. Operation Sindoor proved India's air defense muscle. But it also exposed gaps, ones that Pakistan tried to exploit through waves of drone incursions, many supplied by Turkey and China. Hundreds were launched. All were neutralised. But the lesson stuck – air defense needs to be multi-layered, relentless and everywhere. That is where the QRSAM fits in. Designed by the Defence Research and Development Organisation (DRDO), it is built to intercept fighters, drones and helicopters within a 30 km radius. Not as long-range as the S-400's 400 km or Akash's 100-200 km reach, but perfect for quick and short-range airspace protection in dense threat environments. More importantly, it's Indian-made, fast, precise and combat-ready. Not Enough for a Fortress At Rs 6,000 crore per regiment, scaling up to the Army's full demand alone would cost Rs 66,000 crore. Add the Air Force's likely mirror request and you are staring at a Rs 1.12 lakh crore bill. Expensive? Yes. But what is the price of making the skies over India completely off-limits to 5th-gen fighter jets, drones, cruise missiles or worse? With full deployment, India's air defense would shift from deterrence to denial. Nothing would be able to breach the perimeter. During Operation Sindoor, India's air defenses held. But in military planning, holding is never enough. The military is not asking for luxury, it is asking for survivability. Against future drone swarms, supersonic fighters or long-range missile salvos, six regiments are just a start. If the government greenlights the remaining 16 regiments, the Army and the Air Force both, it would send a message that India is preparing. And once QRSAM rings the nation's skies, even the birds will need clearance to fly.
Mint
3 hours ago
- Mint
Wall Street Week Ahead: Spotlight on Fed rate decision, earnings from Microsoft, Meta Platforms, Apple, Amazon
Wall Street in the week ahead will receive plenty of economic data, Big Tech earnings, and the US Federal Reserve's fifth interest rate decision of the year. The economic calendar will see the release of data such as jobs report, second quarter GDP (Gross Domestic Product) numbers, personal income and spending data, PCE (Personal Consumption Expenditures) Index, and S&P manufacturing PMI report among others. For the Q2 earnings, investors will closely watch financial results from tech giants Microsoft, Meta Platforms, Apple, and e-commerce giant Amazon. On the monetary policy front, market participants were keenly awaiting the interest rate decision from the Federal Reserve, which is widely expected to hold it steady. Post-rate decision, Jerome Powell's press conference will be heavily scrutinized amid enormous criticism from US President Donald Trump. On Friday, Trump said that he believed that Fed Chair Jerome Powellmight be ready to lower rates. He made a rare visit to the central bank on Thursday after calling Powell a "numbskull" earlier in the week for failing to cut rates. On July 29 (Tuesday), separate reports on advanced US trade balance in goods for June, S&P Case-Shiller Home Price Index (20 cities) for May, consumer confidence for July, job openings for June will be released. On July 30 (Wednesday), separate reports on ADP employment for July, GDP Q2, pending home sales for June, FOMC interest rate decision will be declared. Fed Chair Jerome Powell's press conference is also scheduled on Wednesday. On July 31 (Thursday), separate reports on Employment Cost Index Q2, personal income and spending for June, PCE Index for June, and Chicago Business Barometer (PMI) for July will be released. On August 1 (Friday), US employment report for July, S&P final US manufacturing PMI for July, ISM manufacturing for July, construction spending for June, consumer sentiment (final) for July, and TBA Auto sales for July will be released. Following companies are due to report second quarter results in the week ahead — Waste Management, Nucor, Visa, Procter & Gamble, UnitedHealth, Boeing, PayPal, Microsoft, Meta Platforms, Qualcomm, Robinhood, eBay, Apple, Mastercard, Exxon Mobil, and Chevron. data-vars-page-type="story" data-vars-link-type="Manual">US stocks ended higher and dollar firmed on Friday ahead of a big week for market risk. The S&P 500 gained 26.73 points, or 0.42%, to end at 6,390.08 points, while the Nasdaq Composite gained 53.95 points, or 0.26%, to 21,111.90. The Dow Jones Industrial Average rose 213.74 points, or 0.48%, to 44,907.65. In the bond market, the yield on the 10-year Treasury eased to 4.38% from 4.43%. The 2-year Treasury yield held steady at 3.91%.
